Sign in

CIK 0001512762 · Accelerated filer<br>Smaller reporting company

Coherus Oncology, Inc.

Sign in to watch
Ticker
CHRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
273615821
Phone
(650) 649-3530
Business address
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
Former names
Coherus BioSciences, Inc., BioGenerics, Inc.
  1. UPLOAD Other SEC-generated Letter
  2. 4 Open-market sale Chief Financial Officer sold 740 shares at $21.78 ($16,117)
  3. 4 Open-market sale Chief Financial Officer sold 3,159 shares at $20.44 ($64,560)
  4. 4 Open-market sale Chief Operating Officer sold 2,500 shares at $20.03 ($50,075)
  5. 4 Open-market sale Chief Financial Officer sold 6,318 shares at an average $21.71 ($137,154)
  6. 4 Open-market sale Chief Financial Officer sold 3,000 shares at $19.04 ($57,120)
  7. 4 Open-market sale Chief Operating Officer sold 2,500 shares at $19.00 ($47,500)
  8. 10-Q Report Quarterly Report
  9. 8-K Event Results of operations
  10. 4 Open-market sale Chief Operating Officer sold 2,500 shares at $19.20 ($48,000)
  11. 8-K Event Results of operations
  12. 4 Open-market sale Director sold 360,000 shares at an average $22.30 ($8,027,600)
  13. 4 Open-market sale Director sold 317,130 shares at $21.37 ($6,777,068)
  14. 4 Open-market sale Chief Financial Officer sold 6,826 shares at an average $19.85 ($135,514)
  15. 4 Other disposition Director disposed of 178,528 shares (other)
  16. 4 Open-market sale President & CEO sold 32,398 shares at $19.49 ($631,282)
  17. 8-K Event Shareholder vote results
  18. 4 Open-market sale Director sold 257,870 shares at $20.69 ($5,335,330)
  19. S-8 Other Securities Offered to Employees in Benefit Plans
  20. 10-Q Report Quarterly Report

Page 25 of 47 · 923 filings